{"context":{"query":">>mondo>>clinical_trials","source_dataset":"mondo","target_dataset":"clinical_trials"},"stats":{"queried":1,"total":100,"mapped":1},"pagination":{"has_next":true,"next_token":"-1[]MONDO:0007915,73,MONDO:0007915,47,2]["},"schema":"id|brief_title|overall_status|phase|study_type","mappings":[{"input":"MONDO:0007915","source":"MONDO:0007915|systemic lupus erythematosus","targets":["NCT00120887|Lupus Atherosclerosis Prevention Study|COMPLETED|PHASE4|INTERVENTIONAL","NCT00125307|Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00188188|Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease|UNKNOWN|PHASE4|INTERVENTIONAL","NCT00371501|Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus|COMPLETED|PHASE4|INTERVENTIONAL","NCT00392093|Effect of Hormone Replacement Therapy on Lupus Activity|COMPLETED|PHASE4|INTERVENTIONAL","NCT00413361|The Reduction of Systemic Lupus Erythematosus Flares :Study PLUS|COMPLETED|PHASE4|INTERVENTIONAL","NCT00508898|The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria|WITHDRAWN|PHASE4|INTERVENTIONAL","NCT00668330|Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus|COMPLETED|PHASE4|INTERVENTIONAL","NCT00739050|Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED)|TERMINATED|PHASE4|INTERVENTIONAL","NCT00815282|Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT00828178|Efficacy of Fish Oil in Lupus Patients|COMPLETED|PHASE4|INTERVENTIONAL","NCT00866229|Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level|UNKNOWN|PHASE4|INTERVENTIONAL","NCT00911521|Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled Study|COMPLETED|PHASE4|INTERVENTIONAL","NCT01101802|Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE)|COMPLETED|PHASE4|INTERVENTIONAL","NCT01112215|Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Extra-renal Lupus Manifestations|COMPLETED|PHASE4|INTERVENTIONAL","NCT01151644|Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases|UNKNOWN|PHASE4|INTERVENTIONAL","NCT01276782|Levothyroxine in Pregnant SLE Patients|WITHDRAWN|PHASE4|INTERVENTIONAL","NCT01322308|Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus|COMPLETED|PHASE4|INTERVENTIONAL","NCT01359826|The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients|WITHDRAWN|PHASE4|INTERVENTIONAL","NCT01597492|A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)|COMPLETED|PHASE4|INTERVENTIONAL","NCT01632241|Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)|COMPLETED|PHASE4|INTERVENTIONAL","NCT01705977|Belimumab Assessment of Safety in SLE|COMPLETED|PHASE4|INTERVENTIONAL","NCT01753401|Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT02270970|Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy|UNKNOWN|PHASE4|INTERVENTIONAL","NCT02477150|Safety and Immunogenicity of a Zoster Vaccine in SLE|COMPLETED|PHASE4|INTERVENTIONAL","NCT02741960|The Effect of Metformin on Reducing Lupus Flares|COMPLETED|PHASE4|INTERVENTIONAL","NCT02779153|Acthar SLE (Systemic Lupus Erythematosus)|WITHDRAWN|PHASE4|INTERVENTIONAL","NCT02953821|Acthar Gel for Active Systemic Lupus Erythematosus (SLE)|COMPLETED|PHASE4|INTERVENTIONAL","NCT03042260|Prophylactic Trimethoprim/Sulfamethoxazole to Prevent Severe Infections in Patients With Lupus Erythematous|UNKNOWN|PHASE4|INTERVENTIONAL","NCT03098823|A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE|COMPLETED|PHASE4|INTERVENTIONAL","NCT03122431|Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases|COMPLETED|PHASE4|INTERVENTIONAL","NCT03543839|Trial of Belimumab in Early Lupus|RECRUITING|PHASE4|INTERVENTIONAL","NCT04447053|Sequential Belimumab and T-cell Based Therapy in SLE|UNKNOWN|PHASE4|INTERVENTIONAL","NCT04515719|Efficacy and Safety of Belimumab in SLE Patients|COMPLETED|PHASE4|INTERVENTIONAL","NCT04893161|A Model About the Response of Belimumab in SLE|UNKNOWN|PHASE4|INTERVENTIONAL","NCT04908865|Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE)|COMPLETED|PHASE4|INTERVENTIONAL","NCT04956484|Belimumab In Early Systemic Lupus Erythematosus|COMPLETED|PHASE4|INTERVENTIONAL","NCT05559671|Safety of the Herpes Zoster Subunit Vaccine in Lupus|RECRUITING|PHASE4|INTERVENTIONAL","NCT05666336|Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients|UNKNOWN|PHASE4|INTERVENTIONAL","NCT05748925|Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients|COMPLETED|PHASE4|INTERVENTIONAL","NCT05828147|Anti-CD20 Antibodies for Treatment of SLE-PAH|RECRUITING|PHASE4|INTERVENTIONAL","NCT05879419|Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases|ACTIVE_NOT_RECRUITING|PHASE4|INTERVENTIONAL","NCT05899907|Efficacy and Safety of Telitacicept in Early SLE|UNKNOWN|PHASE4|INTERVENTIONAL","NCT05916781|Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus|RECRUITING|PHASE4|INTERVENTIONAL","NCT06411249|A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)|RECRUITING|PHASE4|INTERVENTIONAL","NCT06594068|Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users|RECRUITING|PHASE4|INTERVENTIONAL","NCT06677801|Immune Cell Subsets in SLE Patients Treated with Telitacicept|ACTIVE_NOT_RECRUITING|PHASE4|INTERVENTIONAL","NCT06763783|Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases|ENROLLING_BY_INVITATION|PHASE4|INTERVENTIONAL","NCT06875960|A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132|RECRUITING|PHASE4|INTERVENTIONAL","NCT07077486|Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease|RECRUITING|PHASE4|INTERVENTIONAL","NCT07087912|Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases|NOT_YET_RECRUITING|PHASE4|INTERVENTIONAL","NCT07381465|Efficacy and Safety of IL-1 Inhibitors in Mild to Moderate Systemic Lupus Erythematosus|NOT_YET_RECRUITING|PHASE4|INTERVENTIONAL","NCT00000419|Safety of Estrogens in Lupus: Hormone Replacement Therapy|TERMINATED|PHASE3|INTERVENTIONAL","NCT00000420|Safety of Estrogens in Lupus: Birth Control Pills|COMPLETED|PHASE3|INTERVENTIONAL","NCT00004662|Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Active Systemic Lupus Erythematosus|COMPLETED|PHASE3|INTERVENTIONAL","NCT00004795|Phase II/III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Mild to Moderate Systemic Lupus Erythematosus|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT00005778|High-Dose Intravenous (IV) Cyclophosphamide Versus Monthly IV Cyclophosphamide|COMPLETED|PHASE3|INTERVENTIONAL","NCT00025818|Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome|COMPLETED|PHASE3|INTERVENTIONAL","NCT00035308|Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease|COMPLETED|PHASE3|INTERVENTIONAL","NCT00037128|Study of GL701 in Men With Systemic Lupus Erythematosus|UNKNOWN|PHASE3|INTERVENTIONAL","NCT00053560|To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids|UNKNOWN|PHASE3|INTERVENTIONAL","NCT00065806|Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)|COMPLETED|PHASE3|INTERVENTIONAL","NCT00082511|GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids|COMPLETED|PHASE3|INTERVENTIONAL","NCT00089804|Study of LJP 394 in Lupus Patients With History of Renal Disease|TERMINATED|PHASE3|INTERVENTIONAL","NCT00111306|Study of Epratuzumab in Systemic Lupus Erythematosus|TERMINATED|PHASE3|INTERVENTIONAL","NCT00137969|A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT00189124|Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT00368264|TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )|TERMINATED|PHASE2/PHASE3|INTERVENTIONAL","NCT00381810|A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus|TERMINATED|PHASE3|INTERVENTIONAL","NCT00382837|Study of Epratuzumab in Systemic Lupus Erythematosus|WITHDRAWN|PHASE3|INTERVENTIONAL","NCT00383214|Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)|TERMINATED|PHASE3|INTERVENTIONAL","NCT00410384|A Study of Belimumab in Subjects With Systemic Lupus Erythematosus|COMPLETED|PHASE3|INTERVENTIONAL","NCT00424476|A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)|COMPLETED|PHASE3|INTERVENTIONAL","NCT00430677|Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis|TERMINATED|PHASE2/PHASE3|INTERVENTIONAL","NCT00432354|An Open Labeled Pilot Study of Atorvastatin in Systemic Lupus Erythematosus|UNKNOWN|PHASE2/PHASE3|INTERVENTIONAL","NCT00470522|Study of Methotrexate in Lupus Erythematosus|COMPLETED|PHASE3|INTERVENTIONAL","NCT00504244|Myfortic Versus Azathioprine in Systemic Lupus Erythematosus|TERMINATED|PHASE3|INTERVENTIONAL","NCT00539838|A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)|TERMINATED|PHASE3|INTERVENTIONAL","NCT00611663|Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus Erythematosus|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT00624338|Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT00626197|A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)|TERMINATED|PHASE3|INTERVENTIONAL","NCT00712933|A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057|COMPLETED|PHASE3|INTERVENTIONAL","NCT00724867|A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States|COMPLETED|PHASE3|INTERVENTIONAL","NCT01196091|A Study of LY2127399 in Participants With Systemic Lupus Erythematosus|COMPLETED|PHASE3|INTERVENTIONAL","NCT01205438|A Study of LY2127399 in Participants With Systemic Lupus Erythematosus|COMPLETED|PHASE3|INTERVENTIONAL","NCT01240694|A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Participants With Systemic Lupus Erythematosus|TERMINATED|PHASE3|INTERVENTIONAL","NCT01257802|GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases|TERMINATED|PHASE3|INTERVENTIONAL","NCT01261793|Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)|COMPLETED|PHASE3|INTERVENTIONAL","NCT01262365|Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus|COMPLETED|PHASE3|INTERVENTIONAL","NCT01345253|GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia|COMPLETED|PHASE3|INTERVENTIONAL","NCT01395745|CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus|COMPLETED|PHASE3|INTERVENTIONAL","NCT01408576|Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus|COMPLETED|PHASE3|INTERVENTIONAL","NCT01484496|A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)|COMPLETED|PHASE3|INTERVENTIONAL","NCT01488708|On Open-Label Study in Participants With Systemic Lupus Erythematosus|TERMINATED|PHASE3|INTERVENTIONAL","NCT01597622|BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115|COMPLETED|PHASE3|INTERVENTIONAL","NCT02041091|A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus|TERMINATED|PHASE3|INTERVENTIONAL","NCT02074020|CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis|WITHDRAWN|PHASE3|INTERVENTIONAL","NCT02119156|Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients|COMPLETED|PHASE3|INTERVENTIONAL","NCT02504645|A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus|COMPLETED|PHASE3|INTERVENTIONAL","NCT02514967|CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis|TERMINATED|PHASE3|INTERVENTIONAL"]}]}